Business Context and Reporting Period
This Form 8-K Current Report from TherapeuticsMD, Inc. covers events occurring on May 27, 2021, specifically the Company's 2021 Annual Meeting of Stockholders. The filing details the voting results on five key proposals and the approval of an amendment to the Company's stock incentive plan.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial statements are included in this document.
Material Changes and Voting Results
At the Annual Meeting, stockholders representing 262,186,558 shares (out of 393,190,188 outstanding) voted on the following proposals:
- Proposal 1 (Election of Directors): All nine nominees were elected. Broker non-votes totaled 117,335,261 shares for each nominee.
- Proposal 2 (Executive Compensation): Stockholders approved the non-binding advisory vote on executive compensation for the fiscal year ended December 31, 2020. Votes: 108,714,394 For; 31,639,112 Against.
- Proposal 3 (Option Exchange Program): Stockholders approved the Non-Executive Option Exchange Program. Votes: 121,206,929 For; 22,372,399 Against.
- Proposal 4 (Stock Plan Amendment): Stockholders approved the First Amendment to the 2019 Stock Incentive Plan, increasing the number of shares available by 22,475,000. Votes: 126,566,327 For; 17,584,675 Against.
- Proposal 5 (Auditor Ratification): Stockholders ratified the appointment of Grant Thornton LLP as the independent auditor for the fiscal year ending December 31, 2021. Votes: 249,898,514 For; 9,142,295 Against.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. The document strictly reports on the outcomes of the shareholder vote.
Key Facts for Investor Verification
- Verify the impact of the 22,475,000 share increase to the 2019 Stock Incentive Plan on potential future dilution.
- Note the significant number of Broker Non-Votes (117,335,261) on director elections, indicating shares held in street name where brokers lacked discretionary voting power.
- Confirm the implementation details of the approved Non-Executive Option Exchange Program for employees.
- Review the Definitive Proxy Statement (Schedule 14A) filed on April 14, 2021, for full details on the Stock Incentive Plan amendment and director biographies.